Search
Streptococcus pneumoniae type 12f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10331ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 12f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 12f of *Streptococcus pneumoniae
Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer DurchstechflascheFollitropin
go.drugbank.com/drugs/DB00066ApprovedInvestigationalFollitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF). … with significantly higher estradiol (E2) levels.
Mixtures: Pergoveris 150IU/75IU powder and solvent for solution for injection, MENOGON 75 IU Powder and Solvent for solution for InjectionSynonyms: FSH-aMedrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnIt was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing. … Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone.
Asunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseFosdenopterin
go.drugbank.com/drugs/DB16628ApprovedIn 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A. … [A230088] Fosdenopterin was approved by the FDA on Februrary 26, 2021, for the reduction of mortality in patients with MoCD type A,[L32163] becoming the first and only therapy approved for the treatment
Pentastarch
go.drugbank.com/drugs/DB09111ApprovedWithdrawnWhen administered, pentastarch remains mainly in the circulatory system and hence, it is considered a plasma expander. … It is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation.
Categories: Compounds used in a research, industrial, or household settingKetamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedKetamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. … It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332]
Categories: N-Methylaspartate, agonists, N-Methylaspartate, antagonists & inhibitorsProducts: Ketamin G.L. 10 mg/ml - Injektions-/Infusionslösung in Ampullen, Ketamin G.L. 50 mg/ml - Injektions-/Infusionslösung in AmpullenTivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalIt was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524] … Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74.
Risdiplam
go.drugbank.com/drugs/DB15305ApprovedInvestigationalRisdiplam is an orally bioavailable mRNA splicing modifier used for the treatment of spinal muscular atrophy (SMA). … [L15351,A216871] Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA).
Products: Evrysdi Powder for oral solution 0.75 mg/mL, EVRYSDI POWDER FOR ORAL SOLUTION 0.75 MG/MLPolidocanol
go.drugbank.com/drugs/DB06811ApprovedInvestigationalThe formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600. … Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower
Categories: Compounds used in a research, industrial, or household setting, Sclerosing Agents for Local Injection